The promising role of nivolumab in renal cell cancers.

Abstract:

:The therapeutic efficacy of checkpoint inhibitors across numerous tumor types has resulted in approval for neoplasms such as melanoma and lung cancer. Nivolumab is a fully humanized IgG4 antibody that inhibits immune checkpoint between programmed death 1 (PD-1) on T cells and PD-1 ligand 1 (PD-L1) and ligand 2 (PD-L2) on immune and cancer cells. Motzer and Colleagues published the findings of Nivolumab versus everolimus in advanced kidney cancer in the November issue of the New England Journal of Medicine. This trial showed that nivolumab resulted in better median overall survival of 25 months compared to everolimus at 19.6 months, with a hazard ratio for death at 0.73, meeting pre-specified criterion for superiority in favor of nivolumab. These findings mark the defining beneficial role of immune checkpoint inhibitor therapy in metastatic kidney cancer.

journal_name

Cancer Biol Ther

journal_title

Cancer biology & therapy

authors

Gupta K,Tiu DY,Tiu J,Aragon-Ching JB

doi

10.1080/15384047.2016.1139269

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

123-4

issue

2

eissn

1538-4047

issn

1555-8576

journal_volume

17

pub_type

杂志文章
  • Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.

    abstract::TRA-8, a monoclonal antibody targeting death receptor, has demonstrated high therapeutic effect for triple negative breast cancer (TNBC) in preclinical models. Tamoxifen, the standard of care for ERα-positive breast cancer, induces apoptosis via ERβ, which commonly presents in TNBC cells. The current study investigate...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29183

    authors: Kim H,Samuel SL,Zhai G,Rana S,Taylor M,Umphrey HR,Oelschlager DK,Buchsbaum DJ,Zinn KR

    更新日期:2014-08-01 00:00:00

  • Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer.

    abstract::Long standing chronic pancreatitis is a risk factor for developing pancreatic cancer. Inheritance of polymorphisms in SPINK1 and CFTR are associated with an increased risk of developing pancreatitis. The aim of this study was to determine if patients who carry polymorphisms in SPINK1 and CFTR are at increased risk of ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:

    authors: Matsubayashi H,Fukushima N,Sato N,Brune K,Canto M,Yeo CJ,Hruban RH,Kern SE,Goggins M

    更新日期:2003-11-01 00:00:00

  • Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA).

    abstract::Prostate-Specific Membrane Antigen (PSMA) is a glutamate carboxypeptidase II that is highly expressed by both normal and malignant prostate epithelial cells and by the neovasculature of many tumor types but is not expressed by endothelial cells in normal tissue. PSMA possesses the hydrolytic properties of an N-acetyla...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.6.846

    authors: Mhaka A,Gady AM,Rosen DM,Lo KM,Gillies SD,Denmeade SR

    更新日期:2004-06-01 00:00:00

  • Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death.

    abstract::Activation of MAP kinases is involved in various cellular processes, including immunoregulation, inflammation, cell growth, cell differentiation, and cell death. To investigate the role of p38 MAP kinase activation in the signaling pathway of TRAIL-mediated apoptosis, we compared TRAIL-mediated MAP kinase activation i...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.3.696

    authors: Zhang L,Zhu H,Davis JJ,Jacob D,Wu S,Teraishi F,Gutierrez A,Wang Y,Fang B

    更新日期:2004-03-01 00:00:00

  • Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology.

    abstract::Radiotherapy is a widely used local and regional modality for the treatment of cancer. Despite improved methods of radiation delivery, local recurrence accounts for treatment failure in most patients. Radiosensitizers have been studied as one approach for improving the effectiveness of radiotherapy. Few agents, howeve...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.2.4.495

    authors: Kufe D,Weichselbaum R

    更新日期:2003-07-01 00:00:00

  • A targeted IL-15 fusion protein with potent anti-tumor activity.

    abstract::IL-15 has been actively investigated for its potential in tumor immunotherapy. To enhance the anti-tumor activity of IL-15, the novel PFC-1 construct was designed, which comprises the following 3 parts: (1) IL-15Rα fused with IL-15 to enhance IL-15 activity, (2) an Fc fragment to increase protein half-life, and (3) an...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1071739

    authors: Chen S,Huang Q,Liu J,Xing J,Zhang N,Liu Y,Wang Z,Li Q

    更新日期:2015-01-01 00:00:00

  • Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.

    abstract::Several agents targeting the epidermal growth factor receptor (EGFR) have been FDA-approved to treat cancer patients with varying tumor types including metastatic colorectal cancer. Many patients treated with anti-EGFR therapy however do not respond and those that do initially respond often acquire resistance. Here we...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.28179

    authors: Ung N,Putoczki TL,Stylli SS,Ng I,Mariadason JM,Chan TA,Zhu HJ,Luwor RB

    更新日期:2014-05-01 00:00:00

  • Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses.

    abstract::As a kinase at the crossroads of numerous metabolic and cell growth signaling pathways, glycogen synthase kinase-3 beta (GSK-3β) is a highly desirable therapeutic target in cancer. Despite its involvement in pathways associated with the pathogenesis of several malignancies, no selective GSK-3β inhibitor has been appro...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.1080/15384047.2019.1595283

    authors: Sahin I,Eturi A,De Souza A,Pamarthy S,Tavora F,Giles FJ,Carneiro BA

    更新日期:2019-01-01 00:00:00

  • Intestinal metaplasia with a high salt diet induces epithelial proliferation and alters cell composition in the gastric mucosa of mice.

    abstract::Intestinal metaplasia of the gastric mucosa is an important component in the pathway to adenocarcinoma. The mechanisms that induce the progression from intestinal metaplasia to cancer have not been elucidated. High dietary salt has been known as one of the risk factors for gastric cancer development in humans. Therefo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.6.1734

    authors: Xiao F,Crissey MA,Lynch JP,Kaestner KH,Silberg DG,Suh E

    更新日期:2005-06-01 00:00:00

  • Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.

    abstract::Sunitinib, a multi-targeted tyrosine kinase inhibitor, is frequently incorporated into the management of papillary thyroid carcinoma refractory to standard therapies. Although clinical trials are in progress, the mechanism of action in papillary thyroid carcinomas is not clear, especially regarding the effect on BRAF ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.5.16303

    authors: Jeong WJ,Mo JH,Park MW,Choi IJ,An SY,Jeon EH,Ahn SH

    更新日期:2011-09-01 00:00:00

  • Ras family signaling: therapeutic targeting.

    abstract::Mutationally activated and oncogenic versions of the ras genes were first identified in human tumors in 1982. This discovery prompted great interest in the development of anti-Ras strategies as novel, target-based approaches for cancer treatment. The three human ras genes represent the most frequently mutated oncogene...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.306

    authors: Cox AD,Der CJ

    更新日期:2002-11-01 00:00:00

  • Downregulation of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in non-small cell lung cancer cells.

    abstract::Small-molecule inhibitors of cyclin-dependent kinases (CDKs) are known to induce cell cycle arrest and apoptosis in certain cancer cells. In order to evaluate the antitumor activity of one such inhibitor, GW8510, against human lung cancers, we analyzed the effects of GW8510 on six nonsmall cell lung cancer (NSCLC) cel...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.2.2316

    authors: Dong F,Guo W,Zhang L,Wu S,Teraishi F,Davis JJ,Fang B

    更新日期:2006-02-01 00:00:00

  • Telomerase as a target for cancer immunotherapy.

    abstract::Telomerase is the ribonucleoprotein that enables cancer and stem cells to maintain their telomeres, resulting in unlimited proliferative potential. The catalytic component of telomerase in humans, hTERT, is upregulated in nearly 90% of all cancers, making it the most widely expressed marker of malignancy. With the exc...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.2.2.255

    authors: Nguyen B,Elmore LW,Holt SE

    更新日期:2003-03-01 00:00:00

  • Epigenetic changes in gliomas.

    abstract::Epigenetics are defined, in broad-terms, as alterations in gene expression without changes in DNA sequence. While histone modifications and DNA methylation are two classical means to regulate gene expression, miRNA has also recently been documented to govern gene expression in normal as well as cancer cells. In this r...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.7.9.6992

    authors: Burgess R,Jenkins R,Zhang Z

    更新日期:2008-09-01 00:00:00

  • Chitosan hydrogel for localized gene silencing.

    abstract:OBJECTIVE:To achieve effective delivery of siRNA into target cells in vivo, we have developed a novel approach of siRNA delivery by using local drug delivery systems. RESULTS:The chitosan hydrogel (CH-HG) displayed a liquid-solid phase transition in a temperature-dependent manner and formed an endothermic hydrogel in ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.11.9.15185

    authors: Han HD,Mora EM,Roh JW,Nishimura M,Lee SJ,Stone RL,Bar-Eli M,Lopez-Berestein G,Sood AK

    更新日期:2011-05-01 00:00:00

  • Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD.

    abstract::Resistance to apoptosis is one reason for the poor response of malignant brain tumors to therapy. The PPARgamma-modulating drug Troglitazone downregulates the anti-apoptotic FLIP protein and sensitizes glioblastoma cells to apoptosis induced by the death ligand TRAIL. To investigate the molecular basis of an experimen...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.7.12.6966

    authors: Grund K,Ahmadi R,Jung F,Funke V,Gdynia G,Benner A,Sykora J,Walczak H,Joos S,Felsberg J,Reifenberger G,Wiestler OD,Herold-Mende C,Roth W

    更新日期:2008-12-01 00:00:00

  • Targeting of two aspects of metabolism in breast cancer treatment.

    abstract::Deregulated metabolism is gaining recognition as a hallmark of cancer cells, and is being explored for therapeutic potential. The Warburg effect is a metabolic phenotype that occurs in 90% of tumors, where glycolysis is favored despite the presence of oxygen. Dichloroacetate (DCA) is a pyruvate dehydrogenase kinase (P...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.955992

    authors: Gang BP,Dilda PJ,Hogg PJ,Blackburn AC

    更新日期:2014-01-01 00:00:00

  • Mitogen-activated protein kinase phosphatase-1 inhibition and sustained extracellular signal-regulated kinase 1/2 activation in camptothecin-induced human colon cancer cell death.

    abstract::Camptothecins are commonly used chemotherapeutics; in some models, they enhance signaling via the mitogen-activated protein kinase (MAPK) pathway through effects on upstream kinases. To evaluate the impact of camptothecin (CPT) on MAPKs in human colon cancer, we studied HCT116 and CaCo2 colon cancer cells. We found th...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26044

    authors: Lee M,Young Kim S,Kim J,Kim HS,Kim SM,Kim EJ

    更新日期:2013-11-01 00:00:00

  • PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway.

    abstract::Phosphoinositide-3-kinase regulatory subunit 3(PIK3R3) is overexpressed in different types of human cancer. We previously reported the important role of PIK3R3 in colorectal cancer (CRC). However, the prognosis effect of PIK3R3 in CRC is still remaining unclear. In this study, we explored online clinical databases to ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2017.1416936

    authors: Ibrahim S,Li G,Hu F,Hou Z,Chen Q,Li G,Luo X,Hu J,Feng Y

    更新日期:2018-03-04 00:00:00

  • New paradigms for cancer drug discovery.

    abstract::Discovering drugs has never been an easy task. Traditionally, this task has exclusively been undertaken by large pharmaceutical companies that recovered their high research and development costs by selling expensive medications. Despite the huge amount of time and effort devoted towards drug discovery over the last de...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.2.4.448

    authors: Sager JA,Lengauer C

    更新日期:2003-07-01 00:00:00

  • Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.

    abstract::Antitumor imidazoacridinone C-1311 is a DNA-reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor. Here, we demonstrate the mechanism of C-1311 inhibitory action on novel targets: hypoxia-inducible factor-1α (HIF-1α), vascular-endothelial growth factor (VEGF), and angiogenesis. In a cell-free system, C...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.7.15980

    authors: Paradziej-Łukowicz J,Skwarska A,Peszyńska-Sularz G,Brillowska-Dąbrowska A,Konopa J

    更新日期:2011-10-01 00:00:00

  • The biology of hormone refractory breast and prostate cancer: An NCI workshop report.

    abstract::The molecular regulation of growth and progression of hormone refractory breast and prostate cancers remains challenging. The Division of Cancer Biology, NCI organized a small "think tank" style workshop and invited scientists in relevant areas to assess the state of science on the biology of hormone refractory tumors...

    journal_title:Cancer biology & therapy

    pub_type:

    doi:10.4161/cbt.8.21.9918

    authors: Mohla S,Stearns V,Sathyamoorthy N,Rosenfeld MG,Nelson P

    更新日期:2009-11-01 00:00:00

  • MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.

    abstract::Clear cell RCC is the most common, and more likely to metastasize, of the three main histological types of RCC. Pathologic stage is the most important prognostic indicator and nuclear grade can predict outcome within stages of localized RCC. Epithelial tumors are thought to accumulate a series of genetic and epigeneti...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.27314

    authors: Gowrishankar B,Ibragimova I,Zhou Y,Slifker MJ,Devarajan K,Al-Saleem T,Uzzo RG,Cairns P

    更新日期:2014-03-01 00:00:00

  • Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients.

    abstract::Recent trends in cancer therapy have begun emphasizing the use of precision medicine, especially genetic tools, in the evaluation of malignancies and decision-making. Prostate cancer is a malignancy where the benefits and utility of screening and early treatment are still heavily controversial. A recent paper in the N...

    journal_title:Cancer biology & therapy

    pub_type: 评论,杂志文章

    doi:10.1080/15384047.2017.1345398

    authors: Hauke RJ Jr,Sissung TM,Figg WD

    更新日期:2017-08-03 00:00:00

  • Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.

    abstract:OBJECTIVES:To evaluate the 6-mo overall survival, safety and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer. METHODS:Eligibility included: previously untreated metastatic adenocarcinoma of the pancreas with metastases incurab...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,多中心研究

    doi:10.4161/cbt.23625

    authors: Infante JR,Arkenau HT,Bendell JC,Rubin MS,Waterhouse D,Jones GT,Spigel DR,Lane CM,Hainsworth JD,Burris HA 3rd

    更新日期:2013-04-01 00:00:00

  • MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.

    abstract::Taxol (paclitaxel) and Taxotere (docetaxel) are considered as two of the most important anti-cancer chemotherapy drugs. The cytotoxic action of these drugs has been linked to their ability to inhibit microtubule depolymerization, causing growth arrest and subsequent cell death. Studies by a number of laboratories have...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.10.3215

    authors: Yacoub A,Gilfor D,Hawkins W,Park MA,Hanna D,Hagan MP,Curiel DT,Fisher PB,Grant S,Dent P

    更新日期:2006-10-01 00:00:00

  • EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.

    abstract::The pediatric solid tumor neuroblastoma (NB) often depends on the anti-apoptotic protein, Mcl(-)1, for survival through Mcl(-)1 sequestration of pro-apoptotic Bim. High affinity Mcl(-)1 inhibitors currently do not exist such that novel methods to inhibit Mcl(-)1 clinically are in high demand. Receptor tyrosine kinases...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2014.1002333

    authors: Nalluri S,Peirce SK,Tanos R,Abdella HA,Karmali D,Hogarty MD,Goldsmith KC

    更新日期:2015-01-01 00:00:00

  • Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer.

    abstract::The PROfound trial highlights that there is a benefit in testing genes involved in homologous recombination (HR) and forms the rationale for testing in all patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial also demostrates that olaparib improves progression free survival (PFS), objecti...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1809913

    authors: Chau V,Madan RA,Figg WD

    更新日期:2020-10-02 00:00:00

  • The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest.

    abstract::For years, the growth inhibitory effects of the tumor suppressor p53 were thought to be antagonized predominantly by the ubiquitin ligase, MDM2. It has long been established that MDM2 physically associates with p53 and targets this tumor suppressor for proteasomal degradation. In light of recent findings, it now appea...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.8.1068

    authors: Corcoran CA,Huang Y,Sheikh MS

    更新日期:2004-08-01 00:00:00

  • Weighted gene co-expression network analysis and prognostic analysis identifies hub genes and the molecular mechanism related to head and neck squamous cell carcinoma.

    abstract::Head and neck squamous cell carcinoma (HNSCC) is a lethal disease with suboptimal survival outcomes. In this study, we aimed to find an independent prognostic factor of head and neck squamous cell carcinoma and investigate its effect on tumor cell proliferation, apoptosis, migration progress and cell cycle phase. Weig...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1564560

    authors: Li Q,Chen W,Song M,Chen W,Yang Z,Yang A

    更新日期:2019-01-01 00:00:00